Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octagam 10% in adults with chronic primary immune thrombocytopenia
ISRCTN78894548Phase 3Completed
- Sponsor
- Octapharma
- Start
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of Human normal immunoglobulin G in immune thrombocytopenia (ITP), sponsored by Octapharma. Primary endpoints: Platelet count response and Clinical response categories. Started Aug 2012; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on ISRCTN78894548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN78894548.